MetaVia Inc. 8-K

What Happened

• On May 11, 2026, MetaVia Inc. announced via press release (filed on Form 8-K under Regulation FD) that a late-breaking abstract highlighting DA-1726 has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress, May 27–30, 2026 in Barcelona, Spain.
• DA-1726 is described as a novel dual oxyntomodulin (OXM) analog that targets both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity. A copy of the press release is attached to the filing as Exhibit 99.1. The filing notes that website content referenced in the release is not incorporated into the 8-K.

Key Details

• Filing date: May 11, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Event: Late-breaking abstract accepted for poster presentation at EASL Congress 2026 (May 27–30, Barcelona).
• Drug candidate: DA-1726 — a dual OXM analog targeting GLP1R and GCGR for obesity.
• Press release attached as Exhibit 99.1; report signed by CEO Hyung Heon Kim.

Why It Matters

• Acceptance of a late-breaking abstract for a major medical congress signals that MetaVia will present new or timely research on DA-1726 at a scheduled scientific meeting, creating a near-term visibility event for the program (May 27–30, 2026).
• For investors, the poster presentation is a concrete milestone to monitor—presentation content and any reported data could influence clinical outlook and market perception. The 8-K does not include clinical results or timelines beyond the presentation acceptance.